Sierra Oncology Inc (NASDAQ:SRRA) shares shot up 6.6% on Tuesday . The stock traded as high as $3.15 and last traded at $3.09. 642,516 shares traded hands during mid-day trading, an increase of 76% from the average session volume of 365,398 shares. The stock had previously closed at $2.90.

Several research firms recently weighed in on SRRA. ValuEngine upgraded shares of Sierra Oncology from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research cut shares of Sierra Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, October 26th. Finally, Jefferies Group upgraded shares of Sierra Oncology from a “hold” rating to a “buy” rating in a research report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $4.00.

Sierra Oncology (NASDAQ:SRRA) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.03. research analysts expect that Sierra Oncology Inc will post -0.85 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Sierra Oncology (SRRA) Shares Up 6.6%” was reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2017/12/14/sierra-oncology-srra-shares-up-6-6.html.

Sierra Oncology Company Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.